Send to

Choose Destination
See comment in PubMed Commons below

Bupropion, mirtazapine, and reboxetine in the treatment of depression: Executive summary of final report A05-20C, Version 1.1.


Institute for Quality and Efficiency in Health Care: Executive Summaries [Internet]. Cologne, Germany: Institute for Quality and Efficiency in Health Care (IQWiG); 2005-.
2011 May 30.


The aim of this research is to: assess the benefit of treatment with bupropion, mirtazapine or reboxetine in treating the acute phase of depression, in maintenance therapy (relapse prevention), and in recurrence prevention compared to: treatment with placebo; each other; treatment with other antidepressants; in each case in adult patients with depression. The focus of the investigation was on patient-relevant outcomes.

© IQWiG (Institute for Quality and Efficiency in Health Care).

LinkOut - more resources

Full Text Sources

Other Literature Sources

PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for PubMed Health
    Loading ...
    Support Center